Home / Guides / BMI calculator
BMI first. Then a provider.
BMI calculator for weight loss medication: do you qualify?
By the NexLife Medical Team · Medically reviewed by Adam Kennah, MD · Updated
Zepbound and Wegovy are approved for adults with a BMI of 30 or more, or 27 or more with a weight-related condition. Check yours below; a licensed provider decides.
- BMI 30 or more meets the label line on its own
- BMI 27 to 29.9 meets it with a weight-related condition
- A licensed provider weighs your BMI with your health history
The BMI lines, at a glance
- Label line
- 30 or more, or 27 or more with a weight-related condition, for adults
- Conditions
- High blood pressure, type 2 diabetes or high cholesterol: the FDA’s examples
- CDC obesity
- 30 or greater; overweight is 25 to less than 30
- Compounded
- No FDA label, so a licensed provider decides
A licensed provider decides if treatment is right for you. If you’re not prescribed, you aren’t charged for medication.
4.8 out of 5 on Trustpilot · LegitScript certified
About 3 minutes of health questions. No insurance needed.
Compounded medicines aren’t FDA-approved. A NexLife provider prescribes one only if it offers a significant difference for you compared with an FDA-approved medicine.
- Tell us about you About 3 minutes of health questions
- A licensed provider decides You’re prescribed only if it’s right for you
- Your partner pharmacy ships Usually within 1 to 2 business days, free
Key takeaways
- The label line: Zepbound and Wegovy are approved for adults with a BMI of 30 or more, or 27 or more with a weight-related condition.
- Conditions that count at 27: the FDA named high blood pressure, type 2 diabetes and high cholesterol as examples; it isn’t a closed list.
- BMI is a screening measure. The CDC calls it one potential health indicator, to consider with other factors.
- Under 27? You’re below the line the FDA described for Zepbound and below every adult weight-loss trial behind Wegovy.
- Compounded tirzepatide and semaglutide aren’t FDA-approved. No label sets their line, so a licensed provider decides, case by case.
- At NexLife, compounded tirzepatide is $139 a month on the 12-month plan, or $169 month to month, at every dose.
Free BMI calculator
What is your BMI, and does it meet the line for weight loss medication?
Enter your height, your weight and whether you have a weight-related condition to see your BMI, its CDC category and whether it meets the BMI criteria on the Zepbound and Wegovy labels.
For adults. BMI doesn’t measure body fat directly, and it can’t tell you whether a medicine is right for you: a licensed provider decides that with your whole health history.
The label line
What BMI do you need for weight loss medication?
For Zepbound and Wegovy, a BMI of 30 or more, or 27 or more with at least one weight-related condition, in adults.
That’s how the FDA described Zepbound’s approval on November 8, 2023, and the line the adult weight-loss trials behind both medicines used. Today’s labels put it in words: adults with obesity, or adults with overweight and at least one weight-related condition. So from 27 to 29.9 you need a condition, and from 30 you don’t.
| Medicine or program | The BMI line | Good to know |
|---|---|---|
| Zepbound (tirzepatide) | Adults with a BMI of 30 or more, or 27 or more with a weight-related condition | Also approved for moderate to severe obstructive sleep apnea in adults with obesity |
| Wegovy (semaglutide), shot or pill | Adults with obesity, or overweight with a weight-related condition; its adult trials enrolled people with a BMI of 30 or more, or 27 to 29.9 with a condition | The shot is also approved for ages 12 and up with obesity; for teens, the CDC’s obesity line is the 95th percentile for age and sex |
| Compounded tirzepatide or semaglutide | None: they aren’t FDA-approved, so no label sets one | A licensed provider decides, case by case, and prescribes one only when it offers a significant difference for you |
| Medicare’s GLP-1 Bridge | A BMI of 35 or more on its own, or 27 or more with a listed condition (more conditions count from 30), when you start a GLP-1 | For people 18 or older with Part D; covers Wegovy, Foundayo and the Zepbound KwikPen, not compounded GLP-1s |
Which conditions count at 27? When it approved Zepbound, the FDA named high blood pressure, type 2 diabetes and high cholesterol as examples. Zepbound’s trials also counted obstructive sleep apnea and heart disease, and Wegovy’s trials enrolled adults with type 2 diabetes or heart disease from a BMI of 27. It isn’t a closed list, so your provider decides what counts.
What did the trials find? On average, adults in SURMOUNT-1 lost 20.9% of their body weight on tirzepatide 15 mg over 72 weeks, and adults in STEP 1 lost 14.9% on semaglutide 2.4 mg over 68 weeks. Those are averages for the FDA-approved medicines, not a prediction for you, and compounded versions weren’t studied.
CDC categories
What are the CDC’s adult BMI categories?
Underweight is less than 18.5, healthy weight 18.5 to less than 25, overweight 25 to less than 30 and obesity 30 or greater, for adults 20 and older.
| Category | BMI | Zepbound and Wegovy line |
|---|---|---|
| Underweight | Less than 18.5 | Below it |
| Healthy weight | 18.5 to less than 25 | Below it |
| Overweight | 25 to less than 30 | From 27, only with a weight-related condition |
| Obesity | 30 or greater | Meets it |
| Obesity, class 1 | 30 to less than 35 | Meets it |
| Obesity, class 2 | 35 to less than 40 | Meets it |
| Obesity, class 3 (severe obesity) | 40 or greater | Meets it |
Each range runs up to, but not including, the next number. The calculator above uses these ranges and names the obesity class.
For children and teens, the CDC’s line for obesity is a BMI at or above the 95th percentile for age and sex, so these adult ranges don’t apply.
In their words
What do the FDA, the Wegovy label and the CDC say about BMI?
The FDA and the label draw the line at obesity, or overweight with a weight-related condition; the CDC says BMI is one indicator among others.
When it approved Zepbound in 2023, the FDA put the line in BMI numbers:
“Zepbound (tirzepatide) injection for chronic weight management in adults with obesity (body mass index of 30 kilograms per square meter (kg/m²) or greater) or overweight (body mass index of 27 kg/m² or greater) with at least one weight-related condition (such as high blood pressure, type 2 diabetes or high cholesterol)”
U.S. Food and Drug Administration, FDA approves new medication for chronic weight management, November 8, 2023
Wegovy’s label names the same two groups in words, without the numbers:
“To reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition.”
Novo Nordisk, Wegovy (semaglutide) prescribing information, section 1, Indications and usage (revised June 2026)
The CDC is plain that a BMI is a starting point, not a verdict on your health:
“BMI is one potential health indicator. It should be considered with other factors when assessing an individual's health.”
Centers for Disease Control and Prevention, Adult BMI Categories, last reviewed March 19, 2024
And if your number raises questions, the CDC sends you to a person, not a chart:
“If you have questions about your BMI, talk with your health care provider.”
Centers for Disease Control and Prevention, Adult BMI Categories, last reviewed March 19, 2024
The formula
How do you calculate BMI?
Divide your weight in kilograms by your height in meters squared, or multiply your weight in pounds by 703 and divide by your height in inches squared.
In pounds and inches: at 5 ft 7 in (67 inches) and 200 lb, 200 × 703 = 140,600 and 67 × 67 = 4,489. So the BMI is 140,600 ÷ 4,489 = 31.3: class 1 obesity, which meets the label line on its own.
In kilograms and meters: at 170 cm (1.70 m) and 91 kg, 1.70 × 1.70 = 2.89, so the BMI is 91 ÷ 2.89 = 31.49. Enter those numbers and the calculator shows 31.4: it cuts BMI to one decimal and never rounds up, so a BMI of 29.98 shows as 29.9, overweight.
Close to the line: at 5 ft 4 in and 165 lb, the BMI is 28.3, overweight. That meets the label line only with a weight-related condition.
Weight at each BMI line, by height. The first whole-pound weight that reaches each line, using the CDC’s formula:
| Height | BMI 25 | BMI 27 | BMI 30 | BMI 35 | BMI 40 |
|---|---|---|---|---|---|
| 4 ft 11 in | 124 lb | 134 lb | 149 lb | 174 lb | 199 lb |
| 5 ft 1 in | 133 lb | 143 lb | 159 lb | 186 lb | 212 lb |
| 5 ft 3 in | 142 lb | 153 lb | 170 lb | 198 lb | 226 lb |
| 5 ft 5 in | 151 lb | 163 lb | 181 lb | 211 lb | 241 lb |
| 5 ft 7 in | 160 lb | 173 lb | 192 lb | 224 lb | 256 lb |
| 5 ft 9 in | 170 lb | 183 lb | 204 lb | 238 lb | 271 lb |
| 5 ft 11 in | 180 lb | 194 lb | 216 lb | 251 lb | 287 lb |
| 6 ft 1 in | 190 lb | 205 lb | 228 lb | 266 lb | 304 lb |
| 6 ft 3 in | 201 lb | 217 lb | 241 lb | 281 lb | 321 lb |
25 starts overweight; 27 is the label line with a weight-related condition; 30 starts obesity and meets the line on its own; 35 is the top tier of Medicare’s GLP-1 Bridge; 40 starts class 3 obesity.
What BMI misses
Is BMI accurate?
As a quick screen of weight for height, yes; as a full picture of your health, no: the CDC calls BMI a screening measure and one potential health indicator.
- It doesn’t measure body fat directly. It’s weight for height, the same formula for every adult.
- It’s one indicator. The CDC says to consider it with other factors when assessing your health.
- It doesn’t know your history. A provider also weighs your conditions, your medicines and anything that rules treatment out.
- Its adult ranges aren’t for children or teens, who are compared by BMI percentile for age and sex.
- It can’t predict your results. Trial averages describe groups on FDA-approved medicines, not what any one person will lose.
So a BMI never decides a prescription on its own. If you have questions about your number, the CDC’s advice is to talk with your health care provider.
Step by step
How do you check if you qualify for weight loss medication?
Work out your BMI, compare it with the label line, list your conditions and rule-outs, then let a licensed provider decide.
- Get your BMI. Use the calculator above, or divide your weight in pounds by your height in inches squared and multiply by 703.
- Find your category. On the CDC’s adult scale, overweight is 25 to less than 30, and obesity is 30 or greater.
- Check the label line. Zepbound and Wegovy are approved for adults with a BMI of 30 or more, or 27 or more with at least one weight-related condition.
- List your conditions and medicines. High blood pressure, type 2 diabetes and high cholesterol are the FDA’s examples. Note insulin or a sulfonylurea, which make low blood sugar more likely with these medicines.
- Check what rules it out. A personal or family history of medullary thyroid carcinoma or MEN 2, a serious allergy to the medicine, or pregnancy.
- Let a licensed provider decide. They weigh your BMI with your whole health history. Compounded medicines aren’t FDA-approved, and a provider prescribes one only when it offers a significant difference for you.
A provider decides
Can you get weight loss medication with a BMI under 27?
Not within the line the FDA described for Zepbound, and no adult weight-loss trial in Wegovy’s label enrolled anyone under 27; a licensed provider decides with your whole health history.
BMI 25 to 26.9
That still counts as overweight on the CDC’s scale, but it’s below the label line and below Medicare’s GLP-1 Bridge. Talk with your own provider about what fits.
Not sure about a condition?
The calculator counts “not sure” as no. Bring a list of your diagnoses and medicines to your assessment: whether a condition counts is your provider’s judgment.
Compounded medicine
Compounded tirzepatide and semaglutide aren’t FDA-approved and have no label, so no FDA line applies. A provider prescribes one only when it offers a significant difference for you.
Offers that skip the review
The FDA lists a company that doesn’t require a screening and prescription by a licensed doctor as a telehealth red flag. Walk away from one.
At NexLife, you start with about 3 minutes of health questions, and a licensed provider decides if treatment is right for you. If you’re not prescribed, you aren’t charged for medication. If you are, compounded tirzepatide is $139 a month on the 12-month plan or $169 month to month, the same price at every dose. More on each medicine’s line: tirzepatide BMI requirements and semaglutide BMI requirements.
Vial math
How many units is your tirzepatide or semaglutide dose?
On a compounded vial, the units depend on its strength. Here are the label doses at example strengths, with the math to check your own.
Tirzepatide
| Dose | mL at 25 mg/mL | Units (U-100) | On the label |
|---|---|---|---|
| 2.5 mg | 0.1 mL | 10 units | Starting dose, for 4 weeks |
| 5 mg | 0.2 mL | 20 units | A maintenance dose |
| 7.5 mg | 0.3 mL | 30 units | A step up |
| 10 mg | 0.4 mL | 40 units | A maintenance dose |
| 12.5 mg | 0.5 mL | 50 units | A step up |
| 15 mg | 0.6 mL | 60 units | The maximum, and a maintenance dose |
The math: mL = dose ÷ strength (mg per mL), and units = mL × 100. At 25 mg/mL, 10 mg is 10 ÷ 25 = 0.4 mL, or 40 units.
Semaglutide
| Weeks | Weekly dose | At 2.5 mg/mL | At 5 mg/mL |
|---|---|---|---|
| 1 to 4 | 0.25 mg | 0.1 mL (10 units) | 0.05 mL (5 units) |
| 5 to 8 | 0.5 mg | 0.2 mL (20 units) | 0.1 mL (10 units) |
| 9 to 12 | 1 mg | 0.4 mL (40 units) | 0.2 mL (20 units) |
| 13 to 16 | 1.7 mg | 0.68 mL (68 units) | 0.34 mL (34 units) |
| 17 onward | 2.4 mg | 0.96 mL (96 units) | 0.48 mL (48 units) |
The math: mL = dose ÷ strength (mg per mL); units = mL × 100. At 2.5 mg/mL, 1 mg is 1 ÷ 2.5 = 0.4 mL, or 40 units. At 5 mg/mL, the same 1 mg is 0.2 mL, or 20 units.
25 mg per mL is an example only: it’s the strength of the 15 mg multi-dose vial on Zepbound’s label (15 mg per 0.6 mL). Read the strength on your own vial’s label; your provider sets your dose, in steps at least 4 weeks apart. Every step: the tirzepatide dosage chart. Both strengths are examples only. The same dose is a different number of units at a different strength, so read the strength on your own vial’s label. Your prescription sets your dose and schedule, which may differ from these label steps. Every step: the semaglutide dosage chart.
What would you pay with NexLife?
Tap where you are now. We’ll show your NexLife price next to it, or tell you we’ll match it.
Pick one above to see your price.
Prices from each provider’s own site, checked November 1, 2026. Brand-name and compounded medications are different products: compounded medications aren’t FDA-approved, and a provider prescribes one only when it offers a significant difference for you. Price Match Guarantee† terms apply.
Two medications.
One flat price at every dose.
No membership fee. Provider care, a nutrition plan, coaching and shipping are included. Paying less with another licensed provider? We match your regular monthly price.†
GIP + 12-month plan $139/mo
Tirzepatide
Weekly and dual-action. Care, coaching and shipping included. On a 12-month plan; $169/mo month to month.
Check my eligibilityCompounded, not FDA-approved · Not prescribed? No charge for medication
12-month plan $119/mo
Semaglutide
Weekly
Compounded, not FDA-approved · Not prescribed? No charge for medication
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. Vials shown are illustrations. Always use the strength on your pharmacy’s label. Every plan and price · Price Match Guarantee† terms
The NexLife Price Match Guarantee†
Keep your price.
Upgrade your care.
Already on compounded tirzepatide or semaglutide? Pay less with another licensed U.S. telehealth provider or clinic, and we match your regular monthly price for as long as your plan stays active.† Plus a provider who follows your dose, a nutrition plan, a coaching call and real people 24/7.
- 1Send a receipt from the last 60 days
- 2A NexLife provider reviews your prescription
- 3Pay your matched price, at every dose
Locked while your plan is activeSame price at every doseNo membership fee
†Terms: see the Price Match Guarantee† details below. Compounded medications aren’t FDA-approved; a provider prescribes one only when it offers a significant difference for you.
BMI and weight loss medication: your questions
Fair questions about NexLife
- Will my price go up with my dose?
- No. You pay the same at every dose.
- What if I’m not prescribed?
- You aren’t charged for medication.
- Can I cancel?
- Yes, by email. It takes effect 30 days after we receive it. Plans renew until you cancel; our cancellation policy has the details.
- Do I need insurance?
- No. Pay with an HSA or FSA card, or with Affirm, Klarna or Afterpay at checkout.
What BMI do you need for weight loss medication?
For Zepbound and Wegovy, a BMI of 30 or more, or 27 or more with at least one weight-related condition, in adults. That’s how the FDA described Zepbound’s approval and the line both medicines’ trials used. Compounded versions aren’t FDA-approved and have no label, so a licensed provider decides after reviewing your health history.
What BMI do you need for Zepbound?
A BMI of 30 or more, or 27 or more with at least one weight-related condition, such as high blood pressure, type 2 diabetes or high cholesterol. That’s how the FDA described Zepbound’s approval on November 8, 2023. Zepbound is for adults, and it’s also approved for moderate to severe obstructive sleep apnea in adults with obesity.
What BMI do you need for Wegovy?
Wegovy’s label covers adults with obesity, or with overweight and at least one weight-related condition. Its adult weight-loss trials enrolled people with a BMI of 30 or more, or 27 to 29.9 with a condition such as high blood pressure or high cholesterol. The shot is also approved for ages 12 and up with obesity.
Can you get a GLP-1 with a BMI of 27?
Possibly, if you also have a weight-related condition. A BMI of 27 to 29.9 meets the Zepbound and Wegovy line only with at least one, such as high blood pressure, type 2 diabetes or high cholesterol. Without one, it doesn’t. Either way, a licensed provider reviews your whole health history and decides.
Which conditions count with a BMI of 27?
High blood pressure, type 2 diabetes and high cholesterol are the examples the FDA named when it approved Zepbound. Zepbound’s trials also counted obstructive sleep apnea and heart disease, and Wegovy’s trials enrolled adults with type 2 diabetes or heart disease from a BMI of 27. It isn’t a closed list: your provider decides.
Is BMI accurate?
As a quick screen, yes; as a full picture of your health, no. The CDC calls BMI a screening measure and one potential health indicator, to be considered with other factors when assessing your health. It doesn’t measure body fat directly. If you have questions about your BMI, the CDC suggests talking with your health care provider.
How do I calculate my BMI?
Divide your weight in pounds by your height in inches squared, then multiply by 703; in metric, divide kilograms by meters squared. At 5 feet 7 inches and 200 pounds, that’s 200 × 703 ÷ 4,489 = 31.3, class 1 obesity on the CDC’s scale. The calculator on this page does the math for you.
What BMI is considered obese?
A BMI of 30 or greater, on the CDC’s scale for adults 20 and older. The CDC splits obesity into three classes: 30 to less than 35, 35 to less than 40, and 40 or greater, class 3 or severe obesity. Overweight is 25 to less than 30, and healthy weight is 18.5 to less than 25.
Does Ozempic have a BMI requirement?
No. Ozempic is approved for adults with type 2 diabetes, to improve blood sugar and to lower heart and kidney risks, not for weight loss, so its label has no BMI line. Wegovy is the semaglutide brand approved for weight loss. Compounded semaglutide isn’t FDA-approved for either use.
Do you lose eligibility after you lose weight?
Not by the label alone. Zepbound and Wegovy are approved to help keep weight off long term, not only to lose it, so a lower BMI doesn’t end treatment by itself. Medicare’s GLP-1 Bridge looks at your BMI when you started. Private plans set their own renewal rules, and your provider decides whether you continue.
Important safety information
Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. A provider prescribes them only when they offer a significant difference for you compared with an FDA-approved product. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
Read the full safety information
In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and a faster heart rate. Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other
Tirzepatide can make birth control pills less effective: switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. Both medicines may harm an unborn baby. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider right away if you’re pregnant, planning to be, or breastfeeding.
This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at
† NexLife Price Match Guarantee: for new NexLife members switching from a licensed U.S. telehealth provider or clinic with an active prescription for compounded tirzepatide or semaglutide. We match your regular all-in monthly price there (medication plus any required membership, program or visit fee, on a month-to-month plan); first-month offers, coupons, referral credits and prepaid multi-month rates aren’t matched. Proof from the last 60 days required. A licensed provider must determine that treatment is right for you. Not open to people with Medicare, Medicaid or TRICARE coverage. Full terms.
About NexLife. NexLife is a telehealth and care-coordination platform. Care is delivered through affiliated, physician-owned medical groups, and licensed providers decide whether treatment is right for you. NexLife doesn’t make or compound medication: state-licensed partner pharmacies fill each prescription, and we coordinate the rest. Available only in states where our affiliated providers are licensed.
“Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.”
Who wrote and checked this page
Leads the NexLife Medical Team, which writes and medically reviews NexLife’s guides, including this one.
Checked the BMI math and categories against the CDC, the label line against the FDA’s Zepbound approval and the Zepbound and Wegovy labels, and the trial averages against SURMOUNT-1 and STEP 1.
- Every fact, sourced. Each price and rule links to the page it comes from.
- How we make money. NexLife is a telehealth and care-coordination platform. We earn revenue when people join NexLife.
- Corrections, fast. See something wrong or out of date? Email care@nexlife.us and we’ll fix it.
Paying less elsewhere? We match it.†
Your BMI is step one. A provider decides the rest.
Answer about 3 minutes of health questions, and a licensed provider decides if treatment is right for you: compounded tirzepatide is $139 a month on the 12-month plan or $169 month to month, at every dose.
4.8 out of 5 on Trustpilot · Medical director Adam Kennah, MD (NPI 1144260043) · LegitScript-certified
Compounded medications aren’t FDA-approved. A provider prescribes one only when it offers a significant difference for you.
- 1Tell us about you
Start online with your health history.
- 2A licensed provider decides
Online, or by secure video where your state requires a live visit. You’re prescribed only if treatment is right for you.
- 3We ship it, then stay with you
Our partner pharmacy usually ships within 1 to 2 business days. Free shipping, and questions come to us 24/7, never to the pharmacy.
Sources
- Centers for Disease Control and Prevention. Adult BMI Categories. Last reviewed March 19, 2024; read November 3, 2026.
- Centers for Disease Control and Prevention. BMI frequently asked questions. The BMI formula.
- U.S. Food and Drug Administration. FDA approves new medication for chronic weight management. Zepbound’s approval, November 8, 2023.
- Eli Lilly and Company. Zepbound (tirzepatide) prescribing information. Revised August 2026.
- Eli Lilly and Company, via Drugs@FDA. Zepbound (tirzepatide) prescribing information, revised February 2026 (FDA’s copy). The 15 mg multi-dose vial behind the dose chart’s example strength.
- Novo Nordisk. Wegovy (semaglutide) prescribing information. Revised June 2026; section 1, Indications and usage.
- Novo Nordisk. Ozempic (semaglutide) prescribing information. Revised May 2026.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med, 2022.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002.
- Medicare.gov. Weight loss drugs (the Medicare GLP-1 Bridge). Eligibility and covered drugs.
- Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge. Overview and FAQs.
- U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Telehealth red flags.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Compounded drugs aren’t FDA-approved.
- NexLife. Compounded tirzepatide plans.
- NexLife. Compounded semaglutide plans.
- LegitScript. LegitScript certification record for NexLife.us.
- Ro: weight loss program pricing. Checked November 1, 2026.
- Hims: Zepbound KwikPen. Checked November 1, 2026.
- Hims: Wegovy pill and pen, with membership. Checked November 1, 2026.
- Mochi Health: FAQs (membership and medication prices). Checked November 1, 2026.
- Embody: compounded tirzepatide, one-month supply. Checked November 1, 2026.
- Embody: compounded semaglutide, one-month supply. Checked November 1, 2026.